Elan investor proposes Irish board candidates

ELAN Corp investor Ib Sonderby has proposed four candidates for the Irish drugmaker’s board, including Athena Neurosciences co-founder Larry Fritz.

Athena developed the multiple sclerosis drug Tysabri and was later acquired by Elan. Fritz is the founder of several biotech companies, including Athena, where, as vice-president of research, his work led to the development of what is today Elan’s core science in the areas of multiple sclerosis, Alzheimer’s disease and neuromuscular disorders, Sonderby said.

Fritz also served as president and chief executive of Anadys Pharmaceuticals, a company focused on viral diseases and oncology.